GRAIL, Inc. (GRAL) Earnings Call Transcript & Summary
November 4, 2026
Earnings Call Speaker Segments
Josh Ofman
executiveThank you. Good afternoon, everyone, and thanks for being with us as we go over the results for Q3 of 2026 and talk through some recent business updates. Grail hit several major milestones during this quarter, among them a favorable approval vote from the FDA's advisory committee, plus publication of the NHS-Galleri and PATHFINDER 2 results in the New England Journal of Medicine and Nature Medicine; these clinical and regulatory milestones, which matter a great deal, put us in a strong position as we keep moving toward potential future regulatory approval and reimbursement. Back in January, we submitted our premarket approval application to the FDA for Galleri. Then, on September 23rd, the agency brought together a panel of outside experts to assess Galleri's safety, its effectiveness, and its overall balance of benefits and risks when used for screening to find multiple forms of cancer at an early stage in people aged 50 and up. Galleri holds the distinction of being the initial multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were delighted by the favorable vote. The advisory committee's discussion made clear how demanding the evidence standard is that Grail has established for the entire multi-cancer detection testing space; since that meeting we have kept up interactive dialogue with the FDA, and we anticipate a final ruling by the beginning of Q1 in 2027. Galleri rests on a wide body of evidence demonstrating that it can pick up cancer signals across more than 140 cancer types and subtypes, that its false positive rate is very low, and that it can pinpoint where a positive signal originated, allowing workup to be efficient and well targeted. Based on what has been shown so far, our view is that incorporating Galleri into single-cancer screening recommendations could sharply enhance both how well and how efficiently national screening initiatives perform worldwide. The most striking illustration of this comes from a result in the NHS-Galleri randomized controlled trial. When you combine Galleri with the standard of care, the total number of cancers detected rose by a factor of more than four. In addition, Galleri picked up more stage I and II cancers than the UK's national screening program detected across every cancer and every stage combined. That's a striking result, and it strengthens our confidence that we can contribute to better cancer screening and catch the disease early—ahead of symptoms, at a point when a cure is still possible. Our clinical evidence base is something we take great pride in, and we think it stands on its own; we'll keep presenting and publishing our research at the world's leading forums. In September, findings from our two biggest prospective trials, NHS-Galleri and PATHFINDER 2, appeared in the New England Journal of Medicine and Nature Medicine. This research follows the data we shared at ASCO earlier in the year, and it highlights the numerous clinically meaningful advantages of Galleri. Taken together, these studies show that Galleri has identified more than 140 different cancer types and subtypes. In our view, the NHS-Galleri trial results showed convincing clinical utility. Although we did not observe a combined reduction in stage III and IV cancers, Galleri demonstrated an ability to produce a stage shift in detection, resulting in a clinically meaningful decline in stage IV diagnoses. That represents a historic achievement. Measures such as PPV and safety in both PATHFINDER 2 and NHS-Galleri were robust and consistent across populations and studies. Collectively, these studies demonstrate that Galleri delivers consistent performance across two distinct healthcare systems and two very large screening populations. In our view, these findings provide compelling evidence that incorporating Galleri into standard of care screening could meaningfully increase the count of cancers detected through screening, while maintaining a favorable safety profile. The overall cancer detection figure is a strong indicator of clinical usefulness: screening produced a four- to 6.5-fold rise in detections, nearly 50% of which were early-stage I and II disease, along with a 20% drop in stage IV incidence within a pre-specified set of 12 deadly cancers, a 25% decrease in cancer diagnoses made in the emergency room, and among Galleri-detected stage I through III cancers, over 80% received treatment with curative intent. While we wait for the FDA's decision, our investments are aimed at sharply distinguishing Galleri and eliminating a great deal of the noise and confusion present in the market. We're likewise getting ready to engage with commercial payers and CMS. Looking at how the business performed commercially in 2026, we continued building momentum and were pleased with the volume growth we achieved. During Q3, test volumes climbed 24% compared with the same period a year earlier, and through the first three quarters we have now completed over 174,000 tests — a 36% gain over last year. We added to our provider sales force in June, and as we move past the summer lull, those new team members are still being brought up to full productivity. Beyond that, we are widening access via provider, health system, employer, and digital channels, drawing on both fresh and long-standing partnerships. Our inaugural Epic integration went live as Q3 drew to a close, and we anticipate a number of additional integrations before the year is out. Q3 is usually a fairly slow period, and this year the slowdown was made worse by marketplace effects from negative news coverage regarding the NHS-Galleri results, which carried on through and after ASCO. Along with a highly active competitive environment, that held back growth in Q3. We believe a possible FDA approval would let us make clear how strong Galleri's safety and performance data are, and would underscore that Galleri is the sole MCED test with FDA approval, which would help establish a bifurcated market in which Galleri is clearly differentiated. If FDA approval comes through, Galleri will occupy a category entirely of its own. At present, the marketplace is confused about which MCEDs might hold FDA approval. At present, all MCED tests are lab-developed, but people tend to assume they're all the same—when in reality they differ substantially. Comparing how tests perform in small case-control studies with results from large interventional trials in the screening population just isn't scientifically sound, and in our view, the benefits and harms must be grasped via interventional studies conducted in that screening population. After a favorable FDA advisory committee vote, and with a possible FDA approval on the horizon, we've started accelerating our commercial spending—adding sales force capacity, rolling out our price promotion sooner, and increasing direct-to-consumer advertising outlays. As we work to reshape the market, we anticipate further investment in brand awareness and in setting ourselves apart from competitors down the road. If we get the FDA's green light, Galleri will stand apart as a strong, thoroughly validated test backed by that approval. Overall, it's been an extremely active quarter for Grail. We hit a key regulatory marker when the FDA advisory committee voted in our favor, bolstered the evidence behind Galleri by bringing out our two pivotal clinical trials, and continued pushing commercial uptake while laying groundwork for wide market access. As the undisputed frontrunner in MCED, we're set up strongly to keep expanding. A near-term FDA ruling is something we're anticipating, and should it be favorable, we're getting ready to push for faster growth. We think this achievement will assist in moving forward our conversations with health systems, self-insured employers, payers, and guideline developers, plus build stronger confidence among providers and consumers. Now I'll pass things to Aaron to walk through our third quarter financials.
Aaron Freidin
executiveAppreciate that, Josh, and hello everyone on the line this afternoon. Our Q3 revenue came in at $37.5 million, an increase of $1.3 million, or 4%, over the third quarter of 2025. That third quarter total was split between $37.3 million from screening and $0.2 million from development services. Screening revenue climbed 14% year over year against the third quarter of 2025, and test volumes topped 56,000, which is 24% higher than the third quarter of 2025. Volumes in Q3 landed somewhat below Q2, consistent with the seasonal trend in Galleri sales since we launched — quarters 1 and 3 tend to be softer than quarters 2 and 4 — and it also captures the market headwinds we've been facing. Across the first nine months of 2026, Galleri test volume rose 36% versus the comparable stretch a year earlier. Meanwhile, average selling prices came down, which yielded 24% revenue growth for those nine months over the previous year. Getting ready for an FDA decision, and reacting to weaker growth in the quarter's first two months, we introduced a pricing promotion in September. We recognize that price acts as a major obstacle in the self-pay market, and we anticipate the promotional pricing will drive added demand, consistent with what past experience has shown. Because of that pricing promotion, our Q3 ASP has fallen to roughly $660 per test. In the near term, we're deliberately putting growth and market penetration ahead of margin optimization so we can build market momentum as we get closer to an FDA decision and other significant milestones. Our view is that growing volume deepens the experience of providers and patients, creates more chances for repeat testing, and lowers COGS over time. We've long anticipated that prices would come down over time to support broad-scale adoption, since the MCED legislation links the price to Cologuard. This current pricing promotion will give us valuable data for setting pricing strategy during the interim period before broad reimbursement. As a reminder, the legacy Illumina royalty has been suspended and will resume in late December 2026. During 2026, our quarterly filings have shown how much royalty we would have owed if the suspension weren't in place—Q3, for instance, would have come to $2.6 million. When we report the first quarter of 2027, this royalty will hit gross margin in full for the first time since the company became publicly traded via spin-out. Still, just like in our lab, which runs with a high degree of automation, margins should rise along with volume. Our outlook stays the same: adjusted gross margin in the 50% to 60% range at scale, Illumina royalty included. Looking at where we stand right now, as we get closer to a COGS figure of roughly $230 with the royalty included, we anticipate about a $100 reduction in COGS thanks to scale. Past those scale-driven savings, there are further efforts on our side focused on bringing expenses down and lifting margins, and we plan to tell you more about them at a later point. Turning to the quarter's key results: the net loss for Q3 was $103.6 million, which is 16% higher than what we recorded in the third quarter of 2025. For Q3, non-GAAP adjusted gross profit reached $15.9 million, a decline of $4.1 million, or 20%, relative to the third quarter of 2025. Adjusted gross margin came in at 42% and 46% for the three and nine months ended September 30th, 2026, lower than 55% and 49% for the three and nine months ended September 30th, 2025. Compared to Q3 2026 — sorry, excuse me — comparing Q3 2026 with Q3 2025, the decline in adjusted gross profit and gross margin was mainly due to higher allocated overhead costs stemming from changes in sample mix, a reduction in development services, and a lower ASP. Adjusted EBITDA for the third quarter was negative $92.6 million, meaning the adjusted EBITDA loss grew by $20.9 million, or 29%, versus the third quarter of 2025. Even though we're progressing toward the volume goals we set, those volumes are coming in at a reduced ASP. As we look toward the close of the year, we're updating our outlook for Galleri sales revenue growth for the full year to a range of 17% to 21%. In our view, the promotional pricing we plan for late 2026 will set the stage for quicker expansion in 2027 and afterward. Our guidance on cash burn—capped at $300 million for 2026—remains the same; we ended the quarter holding $788.7 million in cash. With the cash we have on hand, we're funded into 2029 and retain flexibility financially as we advance our main priorities — including the effort to obtain regulatory clearance and wide reimbursement for Galleri here in the U.S. Josh, over to you.
Josh Ofman
executiveAaron, thank you. Ahead of taking your questions, I want to share our view of what lies ahead over the coming months and years. Above all, we are getting ready for a future in which we secure regulatory clearance and wide reimbursement. That is how we intend to succeed over the long run, when we foresee annual screening across the whole population with Galleri, alongside the single-cancer screening tests that are already recommended. We have strong conviction that this approach could substantially enhance population health, given that cancer ranks as the top cause of death among adults aged 50 and older. For the immediate future, three main priorities guide us: first, maintaining our dialogue with the FDA while it reviews our PMA submission; second, laying the groundwork for reimbursement, which includes further broadening our already substantial body of evidence; and third, converting the market momentum we are observing into lasting, repeat demand as we establish a two-tiered MCED market. The favorable FDA advisory committee result, along with the NHS-Galleri and PATHFINDER 2 publications, has put us in the strongest position we have ever occupied; we are deliberate about how we invest in the field and are offering a reduced promotional price to build scale and get ready for broad market access. We see this as the correct trade-off for patients and for long-term shareholder value. Galleri sits at the start of its growth curve, and we have made long-term investments that will let us keep evolving and hold clear leadership in the multi-cancer early detection field. We believe no one else matches the rigor and scope of our clinical data and our test performance. Although the market is getting more crowded with tests that promote different performance metrics and results, Galleri is the only one that has published and presented data demonstrating strong and consistent performance in the actual screening population, which is our intended use; we keep investing to capture a long-term market where regular annual testing is both available and reimbursed; we think we have found the strongest biological signal for detecting cancer, we have assembled the most robust data package with strong regulatory and payer engagement, and we are well-positioned to move into clinical guidelines. More milestones lie ahead, and we are enormously proud of what we have accomplished and of our leadership in this field. Detecting multiple cancers early could genuinely reshape what patients go through and cut down on metastatic disease across a range of cancer types. At the scale of whole populations, no other intervention has shown this. With the most recent data readouts in hand, I can now picture a future in which metastatic cancer diagnoses are wiped out within our lifetime. None of this would be achievable without the people enrolled in our clinical studies, the clinicians and health systems who have adopted Galleri in their practice, and the Grail team, whose efforts across the last 10 years to bring us to this point have been nothing short of extraordinary. On behalf of everyone here, thank you. We appreciate our shareholders sticking with us while we strive toward a future where spotting cancer early becomes a standard part of regular medical care. With that said, operator, please go ahead and open the lines so we can take questions.
Subbu Nambi
analystI’ve got a question about AdCom. During the AdCom, multiple panelists were in favor of mandating documented shared decision-making, and a few specifically voiced worries regarding digital health platforms. If the final label ends up requiring active consent or documented shared decision-making from you, what impact would that have on ordering via Hims, Function, or your own telehealth? Has the FDA asked you any follow-up questions that addressed this?
Josh Ofman
executiveHi, Subbu, thanks for asking; we have not actually received follow-up FDA questions on that topic. In my view, shared decision-making is still something very central to clinical care across every aspect, and it’s something patients expect to occur at all times between them and their provider. No, it has not come up in our FDA discussions so far.
Subbu Nambi
analystThanks for that, Josh. I realize you mentioned it was a related follow-up, but mine is unrelated: what is your latest thinking on pricing and price elasticity for Galleri? Where do you expect to finish 2026 in terms of ASPs, and what would be a realistic starting point for 2027 ASPs, given that you are prioritizing more volume over ASP?
Josh Ofman
executiveThanks, Subbu. Aaron, would you like to go ahead and take that?
Aaron Freidin
executiveSubbu, that's a great question. As we mentioned earlier, we're embracing the pricing elasticity, and we witnessed that during this quarter. When it comes to '27, it's premature to comment. We'll update you on what ASPs, volumes, and all those details will look like next year. For the remainder of the year, as we noted, we truly kicked this off in September, the final month of the quarter. We're on a solid path. I would anticipate our ASPs for the year to be roughly consistent with where we stand at present.
Subbu Nambi
analystUnderstood. Many thanks, everyone.
Dan Brennan
analystThank you, and thanks for the questions. Perhaps starting with the FDA point: you said early '27 — I take it that means January? Did the FDA provide a date? Any detail you can give on that? And you also said you've had active discussions with the FDA. Is there anything you can share on how those talks have gone — for instance, is the base case like the AdCom, meaning a kind of all-comers label, and perhaps some language about screened cancers? Could you share anything about what your base case looks like and how the discussion is progressing?
Josh Ofman
executiveOf course, thanks for the question. Harpal, would you like to...
Harpal Kumar
executiveYeah. Hi, Dan — Harpal here. As for those ongoing talks with the FDA, they're quite active conversations, and the interactions keep being very positive. We're in very active label negotiations, and yeah, look, we're saying early Q1. I won't get more specific than that. We don't have a specific date from the FDA in answer to your question; regarding the actual label negotiations, we anticipate that the intended use will align with the data that we put forward to support the application, and that will support the broad unmet need for additional cancer screening. As we've told you before, we anticipate being able to report results for any cancer type we detect.
Dan Brennan
analystUnderstood. So on the volume side of the competitive landscape, it seems like for 4Q you might be anticipating something around 20% volume growth. I'm just curious whether you've observed any near-term upside following the AdCom, and regarding the capacity to reverse things once FDA approval comes, help us think through how you'll be able to set yourselves apart from all the other tests out there, with FDA. Is there any concern that you won't be able to stand out dramatically, even with the approval, given that, as you said, the competitive noise factor is quite high? Thank you.
Josh Ofman
executiveThanks, Dan. Andy, do you want to take that?
Andy Partridge
executiveThanks, Dan. Following the advisory committee, we saw a great deal of enthusiasm from prescribers. When we look specifically at the clinic and health system channel — which, as you know, is our biggest business — we in fact hit the volume targets we set back in Q3. We clearly benefited from a tailwind created by the advisory committee, along with the pricing promotion we ran, which drove substantial healthcare provider activation; we observed considerable reactivation of dormant prescribers, and we have kept making headway with health systems too. Based on market research we conducted with providers, we believe Galleri can be differentiated from the other MCEDs, and once we factor an FDA approval into that picture, we are confident that we can differentiate our product and reach that market bifurcation Josh has described.
Kyle Mikson
analystHi everyone, thanks for those questions. Perhaps I'll pick up where Dan was going. The fourth quarter, hopefully, is one that gets a boost from the AdCom. In the third quarter, you mentioned there was some negative sentiment lingering after ASCO, and I suppose there were other factors too. You may also have the Epic tailwind. Could you maybe discuss what you're seeing on those fronts regarding Epic or any other partnerships? Then it just seems like we might need to wait for this FDA approval in late 1Q before volume inflects. Maybe just say whether that's a logical way to think about it.
Josh Ofman
executiveThanks, Kyle. I'll address that — there's decent momentum right now coming out of the AdCom and ahead of a possible FDA approval. I'll have Andy speak to how he expects that momentum to carry forward.
Andy Partridge
executiveKyle, you had a question about Epic. Our Epic integration is now underway, and we have our first health system live on Epic. We also have several health systems scheduled for the Epic integration, both through the remainder of this year and into next year. That will allow Galleri to be folded into prescribing behavior within health systems; we have everything in place for our launch after FDA approval that will, as we discussed earlier, set Galleri apart from other MCEDs. We believe it will drive further health system adoption, possibly open up guideline discussions, and an FDA approval, as we communicated before, will let us begin more active engagement with payers going forward as we ultimately pursue broad reimbursement. I would also note, Kyle, on your point, that FDA approval gives physicians a reason to choose Galleri that is really easy to understand and easy to defend. It genuinely aids differentiation and creates a product class in which Galleri will stand on its own compared with all the other MCEDs on the market that have scant data and are in very early development or experimental phases.
Kyle Mikson
analystGreat. So perhaps, with FDA approval getting close, does that put pressure on CMS to develop this NCD policy over time? In a similar vein, some media outlets suggested HHS was urging USPSTF to add MCED. Could you comment on any talks with USPSTF, particularly given the midterms? Thanks.
Josh Ofman
executiveAbsolutely. Hello, Kyle. Josh here; we aren't able to discuss any conversations with USPSTF. Many questions remain regarding how that will take form or take shape. On the CMS side, following FDA approval, since we've already engaged CMS, we intend to engage them to open their national coverage analysis. We must wait for FDA approval before starting that, but we've been engaging with CMS regarding our data and regarding the REACH study throughout.
Harpal Kumar
executiveAppreciate that, Angela. It's Harpal speaking. A few separate things to cover. On the UK side, regulatory clearance is already in hand. The UK now operates a somewhat distinct framework known as the UKCA mark, and we hold that already, so no regulatory approval wait applies there. Turning to the remainder of Europe, our IVDR submission has gone in and that review is in progress. Generally that takes roughly 12 months or so; we are hoping for a readout at some point in 2027, though the process is already well advanced. Regarding the NHS, conversations are carrying on continuously; these are matters that overall budget factors for the NHS will influence, along with the political climate, so to speak. Discussions with the NHS are active and we will keep moving those forward, but I cannot offer any indication of timing right now. Thanks for that. Moving to international, how is the Samsung financing arrangement coming along this quarter? What commercial activities have you carried out in those markets so far? That means Korea and Japan.
Aaron Freidin
executiveLet me begin with the financing side. We completed a $110 million round with them during Q2 of '26, and that portion of the relationship is now finished. On the commercial side, I'll pass things to Andy so he can describe where we stand with them.
Andy Partridge
executiveConversations with Samsung about bringing this to market in Korea have begun, and they are still underway; as things move forward, we will keep you informed at later points. Thank you.
Karan Patel
analystHi everyone, Karan Patel here, sitting in for David Westenberg. I've got a couple of questions. Maybe we can return to the FDA and the possibility of a label restriction — can you give us any color or guidance on where you think an upper age limit might land, and what portion of volume comes from the 65-and-above group, plus the 50-to-65 band as well?
Harpal Kumar
executiveThis is Harpal, thanks. At this point I'm not able to comment on the specifics of label negotiations with the FDA; our discussions continue to move forward consistent with the data we submitted to the FDA, which examines populations of 50 and above — that's what we're considering right now. As for how it splits between 50 to 65 and 65 and above, I'd say that ought to simply mirror overall population volumes rather than any particular label discussions.
Karan Patel
analystGot it. Perhaps the population level mirrors the volumes we're seeing now; so my follow-up is simply about sales productivity. My sense is that your reps have more or less hit a stable point where you can talk about full productivity and so on?
Aaron Freidin
executiveAndy, go ahead.
Andy Partridge
executiveAs I believe we laid out earlier, back in June we grew the sales team from 90 up to 120 reps; that build-out is clearly finished, and we expect this group to keep delivering more productivity through year-end. As I mentioned before, we in fact hit our volume targets in that channel where we added to the sales force, since that group concentrates on our clinic business, where we've observed robust growth in new prescribers, robust reactivation of dormant prescribers, and robust repeat testing behavior from physicians too.
Karan Patel
analystUnderstood. Thanks, everyone.
Aaron Freidin
executiveGlad to. Just like we discussed, we're putting money in now because of the favorable AdCom, and that will track with our plan through the remainder of the year. As for 2027, that plan isn't finished yet, so we'll provide further guidance down the road. My expectation is that we'll keep capitalizing on the FDA approval once it comes through.
Josh Ofman
executiveI believe we're going to keep putting money into our commercial marketing and the way we communicate our competitive position, and I think that FDA approval, assuming we get it, will be really useful in helping us keep differentiating, and I think the tactics we've already been using in the market, we're just going to keep ramping those up once that approval comes through. Great. I think this was the first full quarter in which that sales force was out delivering the message on the full NHS-Galleri and PATHFINDER 2 results. So what has the feedback been from physicians who were already ordering since that's been out there, and how effective has your team been at getting your message to resonate with providers, given some of the noise you mentioned earlier on the call?
Andy Partridge
executiveAppreciate the question. The data from NHS-Galleri and PATHFINDER 2 really set us apart. No other product besides Galleri has demonstrated a reduction in stage IV. That's an incredibly persuasive point when we bring it to physicians, and with the full papers now out in New England Journal of Medicine and Nature Medicine, on top of the advisory committee, plus the pricing promotion, there's been a great deal of enthusiasm across the clinic and health system channels — which was a major reason we hit our Q3 volume targets in that channel, the biggest one for Galleri, as you know.
Brad Bowers
analystCan you hear me okay?
Brad Bowers
analystOkay, thank you for taking the questions. I appreciate the time. What I wanted to hear about — we now have some analogs on the volume trajectory for screening tests. You touched on this somewhat in the opening remarks, but FDA is a nice kick, though reimbursement matters even more, and then guidelines — it seems like you kind of share this view, but I just wanted to get into how we should, I guess, think about medium-term modeling, and the step-ups that go along with that.
Aaron Freidin
executiveThis is Aaron, and I'll give it a try. I think, as Andy alluded to, with the FDA approval we're going to be trying to go out and establish a differentiated product, to set ourselves apart from the rest of the competition, which I think will help put us in a better position against the market. As far as modeling that growth with an FDA-approved product that's still in a self-pay market, I think that's a little bit more challenging, and as I said, when we get to 2027 guidance, we'll give you more detail there. I feel comfortable saying that, comparatively, FDA approval alone versus a reimbursement or guideline is going to be a lower inflection point, obviously, and I'm sure you'd agree. I don't know, Josh, Andy, if you also want to...
Josh Ofman
executiveNo, I’d simply put it this way: what the FDA approval really gives us is the gateway to coverage and reimbursement at this point; we’re going to be dramatically speeding up our engagement with payers and CMS from here on. Now that we have an FDA-approved product, there’s an opportunity — remember that Medicare, under legislation passed this year, can cover MCEDs only if they are FDA approved. That gives us that opportunity uniquely, and we’re going to pursue it very rigorously going forward. Obviously, we’re going to be very active in engaging commercial payers now from this point on. That FDA approval has always been the major gateway for it. Andy, anything you’d like to add?
Andy Partridge
executiveI believe you've addressed that thoroughly, Josh. We've assembled a team that's out there engaging with payers right now. We've had some wins already with payers—select regional plans such as Priority Health and Saiho, and Medicare Advantage plans including Align and Priority Health have already granted coverage for Galleri. As Josh mentioned, the FDA approval is now set to expand these discussions beyond regional payers to national payers as well, spanning both self-insured employers with ASO plans and Medicare Advantage plans moving forward; we're going to ramp up those payer engagement efforts on the back of a potential FDA approval.
Brad Bowers
analystThat's fantastic color, really appreciate it. Since we're discussing commercial payers, you folks are clearly savvy on pricing, given your experience in the self-pay market and the fact that pricing promotions paid off this quarter. Will you be able to bring that data to the payers? Naturally patients want lower out-of-pocket costs, and payers will attempt to work out, I suppose, how to optimize volume and price, but obviously you want to ensure you're being appropriately reimbursed for the results you deliver. How are all those factors being weighed? Thank you.
Josh Ofman
executiveIt's part of our plan. The payer team we've assembled, now engaging with payers, also collaborates with our employer team that calls on benefits managers for self-insured employers; they have a complete value proposition and value dossier for Galleri that includes budget impact models they're discussing with these payers and self-insured employers, all aimed at expanding coverage and covered lives, since ASO plans for self-insured employers and Medicare Advantage plans will be part of our focus going forward, assuming the potential FDA approval we're currently in discussions with the agency about. It's still early days, too soon to comment on matters like cost sharing, requirements or copays, but as we dig deeper and engage more thoroughly with all these regional and national payers, we'll have more to say about that down the road.
Operator
operatorThanks. At this point, we don’t have any more questions. Everyone, that brings the call to an end. You’re free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete GRAIL, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to GRAIL, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in GRAIL, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.